Biotech | October 29, 2021
Merck expands capacity for Antibody Drug Conjugate (ADC), therapies
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
Two leaders in science combine complementary best-in-class technologies for biologics manufacturing customers
The Phase 3 study is designed to bridge data collected from the vaccine efficacy trial conducted in India to the U.S. population
Filing marks first protein-based vaccine submitted to MHRA for authorization
Support from DFC will help produce one billion vaccine doses by the end of 2022
The list of kids with co-morbidities eligible for vaccination would be announced by the government
Strengthens supply chain continuity with first manufacturing facility outside of the U.S.
The implant is surgically inserted into the eye during a one-time, outpatient procedure and refilled every six months
Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option
It has exercised intellectual property options from IP Group regarding research results generated by the UK Cystic Fibrosis Gene Therapy Consortium, and from Oxford Biomedica regarding their lentiviral vector technology
Subscribe To Our Newsletter & Stay Updated
